DOXILine.com - Medicare Guideline Archives

Introduction

Medicare Guideline Archives

Medicare Guideline Update Table

State Medicare Guidelines / CMS 1500

Select

BILLING & REIMBURSEMENT

Medicare Guideline Archives

Select State or Region

A

Alabama

	06/01/2010 - Present
	05/01/2010 - 05/31/2010

Alaska

	04/07/2010 - Present
	06/09/2009 - 04/06/2010

Arizona

	04/07/2010 - Present
	06/09/2009 - 04/06/2010

Arkansas

	05/01/2010 - Present
	04/22/2010 - 04/30/2010

C

California

	02/26/2009 - Present
	04/01/2008 - 02/25/2009

Colorado

	06/11/2010 - Present
	04/23/2010 - 06/10/2010

Connecticut

	06/01/2010 - Present
	03/03/2010 - 05/31/2010

D

Delaware

	04/15/2010 - Present
	01/14/2010 - 04/14/2010

District of Columbia

	04/15/2010 - Present
	01/14/2010 - 04/14/2010

F

Florida

	02/16/2009 - Present
	01/01/2009 - 02/15/2009

G

Georgia

	06/01/2010 - Present
	05/01/2010 - 05/31/2010

H

Hawaii

	02/26/2009 - Present
	04/01/2008 - 02/25/2009

I

Idaho

	04/06/2010 - Present
	06/09/2009 - 04/05/2010

Illinois

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

Indiana

	06/01/2010 - Present
	03/03/2010 - 05/31/2010

Iowa

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

K

Kansas

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

Kentucky

	06/01/2010 - Present
	03/03/2010 - 05/31/2010

L

Louisiana

	05/01/2010 - Present
	04/22/2010 - 04/30/2010

M

Maine

	06/01/2009 - Present
	05/01/2009 - 05/31/2009

Maryland

	04/15/2010 - Present
	01/14/2010 - 04/14/2010

Massachusetts

	06/01/2009 - Present
	05/01/2009 - 05/31/2009

Michigan

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

Minnesota

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

Mississippi

	06/01/2010 - Present
	05/01/2010 - 05/31/2010

Missouri

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

Montana

	04/07/2010 - Present
	06/09/2009 - 04/06/2010

N

Nebraska

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

Nevada

	02/26/2009 - Present
	03/01/2008 - 02/25/2009

New Hampshire

	06/05/2009 - Present
	05/01/2009 - 06/04/2009

New Jersey

	04/15/2010 - Present
	01/14/2010 - 04/14/2010

New Mexico

	06/11/2010 - Present
	04/23/2010 - 06/10/2010

New York

	06/01/2010 - Present
	03/03/2010 - 05/31/2010

North Carolina

	10/01/2009 - Present
	12/02/2008 - 09/30/2009

North Dakota

	04/07/2010 - Present
	06/09/2009 - 04/06/2010

O

Ohio

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

Oklahoma

	06/11/2010 - Present
	04/23/2010 - 06/10/2010

Oregon

	04/07/2010 - Present
	06/09/2009 - 04/06/2010

P

Pennsylvania

	04/15/2010 - Present
	01/14/2010 - 04/14/2010

R

Rhode Island

	06/01/2009 - Present
	12/01/2008 - 05/31/2009

S

South Carolina

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

South Dakota

	04/07/2010 - Present
	06/09/2009 - 04/06/2010

T

Tennessee

	06/01/2010 - Present
	05/01/2010 - 05/31/2010

Texas

	06/11/2010 - Present
	04/23/2010 - 06/10/2010

U

Utah

	04/07/2010 - Present
	06/09/2009 - 04/06/2010

V

Vermont

	06/05/2009 - Present
	05/01/2009 - 06/04/2009

Virginia

	06/11/2010 - Present
	04/23/2010 - 06/10/2010

W

Washington

	04/07/2010 - Present
	06/09/2009 - 04/06/2010

West Virginia

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

Wisconsin

	07/01/2010 - Present
	06/01/2010 - 06/30/2010

Wyoming

	04/07/2010 - Present
	06/09/2009 - 04/06/2010

Indications:

DOXIL^® (doxorubicin HCl liposome injection) is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after prior platinum-based therapy
DOXIL in combination with VELCADE^® (bortezomib) is indicated for the treatment of patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy
DOXIL is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy

IMPORTANT SAFETY INFORMATION

BOXED WARNINGS:
Cardiotoxicity, infusion reaction, myelosuppression, liver impairment, substitution

The use of DOXIL may lead to cardiac toxicity. Myocardial damage may lead to congestive heart failure and may occur as the total cumulative dose of doxorubicin HCl approaches 550mg/m²

Prior use of other anthracyclines or anthracenediones should be included in calculations of total cumulative dose
Cardiac toxicity may also occur at lower cumulative doses (400 mg/m²) in patients with prior mediastinal irradiation or who are receiving concurrent cyclophosphamide therapy

Acute infusion-related reactions including, but not limited to, flushing, shortness of breath, facial swelling, headache, chills, back pain, tightness in the chest or throat, and/or hypotension have occurred in up to 10% of patients treated with DOXIL. In most patients, these reactions have resolved within several hours to a day once the infusion is terminated. In some patients, reactions resolved with slowing of the infusion rate

Serious and sometimes life-threatening or fatal allergic/anaphylactoid-like infusion reactions have occurred. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use
The initial rate of infusion should be 1mg/min to minimize the risk of infusion reactions

Severe myelosuppression may occur
DOXIL dosage should be reduced in patients with impaired hepatic function
Accidental substitution has resulted in severe side effects. Do not substitute for doxorubicin HCl on a mg per mg basis.

Contraindications

Patients with a history of hypersensitivity reactions to a conventional doxorubicin formulation or the components of DOXIL
Nursing mothers

Additional Safety Information

Cardiac function should be carefully monitored

Congestive heart failure or cardiomyopathy may occur after discontinuation of anthracycline therapy
For patients with a history of cardiovascular disease, or if the results of cardiac monitoring indicate possible cardiac injury, the benefit of therapy must be weighed against the risk of myocardial injury
In the randomized multiple myeloma study, 25 patients (8%) in the VELCADE for Injection arm and 42 patients (13%) in the VELCADE plus DOXIL arm experienced left ventricular ejection fraction decrease (defined as absolute decrease > 15% over baseline or a > 5% decrease below institutional lower limit of normal)

Myelosuppression may occur; frequently monitor complete blood count (including platelet count), at least prior to each dose of DOXIL

In patients with recurrent ovarian cancer or AIDS-related Kaposi's sarcoma, hematologic toxicity (based on platelet count or absolute neutrophil count) may require dose reduction or delay in administration of DOXIL
In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin level, or neutropenia with fever) may require dose reduction, delay in administration, or suspension of DOXIL and/or VELCADE
Persistent severe myelosuppression may result in superinfection, neutropenic fever, or hemorrhage
Sepsis occurring during neutropenia has resulted in discontinuation of treatment and in rare cases of death

DOXIL may potentiate the toxicity of other anticancer therapies, especially hematologic toxicities, when used in combination with other therapies that suppress bone marrow
Hand-foot syndrome (HFS) may occur during therapy with DOXIL

Based on HFS toxicity grade, dose reduction, delay in administration, or discontinuation of DOXIL may be required
HFS was generally observed after 2 to 3 cycles of treatment, but may occur earlier

The reaction was mild in most patients, resolving in 1 to 2 weeks
The reaction can be severe and debilitating in some patients, resulting in discontinuation of therapy

DOXIL is an irritant, not a vesicant; use precautions to avoid extravasation
DOXIL can cause fetal harm when used during pregnancy
Recall reaction has occurred with DOXIL administration after radiotherapy
DOXIL may interact with drugs known to interact with the conventional formulation of doxorubicin HCl
In patients with recurrent ovarian cancer, the most common all-grade adverse reactions (ARs) > 20% (DOXIL vs topotecan, respectively) included: asthenia (40% vs 51%), fever (21% vs 31%), nausea (46% vs 63%), stomatitis (41% vs 15%), vomiting (33% vs 44%), diarrhea (21% vs 35%), anorexia (20% vs 22%), dyspnea (15% vs 23%), HFS (51% vs 1%), and rash (29% vs 12%)

In addition, 19% vs 52.3% reported alopecia (all grades).
Grade 3/4 hematologic ARs reported in > 5% (DOXIL vs topotecan, respectively) were neutropenia (12% vs 76%) and anemia (6% vs 29%)

In patients with multiple myeloma, the most common all-grade ARs > 20% (VELCADE plus DOXIL vs VELCADE, respectively) included: neutropenia (36% vs 22%), thrombocytopenia (33% vs 28%), anemia (25% vs 21%), fatigue (36% vs 28%), pyrexia (31% vs 22%), asthenia (22% vs 18%), nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%), constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral neuropathy (42% vs 45%), neuralgia (17% vs 20%), and rash (22% vs 18%)

In addition, 19% vs < 1% reported HFS

In patients with AIDS-related Kaposi's sarcoma, ARs reported in > 5% of DOXIL-treated patients were: neutropenia (ANC < 1000/mm³, 46%; < 500/mm³, 11%), anemia (Hb < 10 g/dL, 58%; < 8 g/dL, 16%), thrombocytopenia (< 150,000 platelets/mm³, 61%), nausea (18%), asthenia (7%), fever (8%), alopecia (9%), vomiting (8%), diarrhea (5%), and stomatitis (5%)

Please click here for DOXIL full Prescribing Information, including Boxed WARNINGS